A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.

The Journal of Clinical Investigation
Kenta MatsudaMark Connors

Abstract

BACKGROUNDTo understand the features of a replicating vaccine that might drive potent and durable immune responses to transgene-encoded antigens, we tested a replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or nasal spray.METHODSViral shedding from the nose, mouth, and rectum was measured by PCR and culturing. H5-specific IgG and IgA antibodies were measured by bead array binding assays. Serum antibodies were measured by a pseudovirus entry inhibition, microneutralization, and HA inhibition assays.RESULTSAd4-H5-Vtn DNA was shed from most upper respiratory tract-immunized (URT-immunized) volunteers for 2 to 4 weeks, but cultured from only 60% of participants, with a median duration of 1 day. Ad4-H5-Vtn vaccination induced increases in H5-specific CD4+ and CD8+ T cells in the peripheral blood as well as increases in IgG and IgA in nasal, cervical, and rectal secretions. URT immunizations induced high levels of serum neutralizing antibodies (NAbs) against H5 that remained stable out to week 26. The duration of viral shedding correlated with the magnitude of the NAb response at week 26. Adverse events (AEs) were mild, and peak NAb titers were a...Continue Reading

References

Oct 1, 1990·Epidemiology and Infection·K A CallowD A Tyrrell
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·H S GinsbergG A Prince
Apr 11, 2003·Vaccine·Catherine Gerdil
Jan 1, 1958·A.M.A. Archives of Internal Medicine·W S JORDAN
Dec 24, 2003·International Reviews of Immunology·Drew L LichtensteinWilliam S M Wold
Jul 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kathryn B RenegarPeter F Wright
Nov 9, 2007·The New England Journal of Medicine·Ian J AmannaMark K Slifka
Dec 8, 2007·Current Opinion in Biotechnology·Marjorie Robert-Guroff
Jul 14, 2010·American Journal of Respiratory and Critical Care Medicine·John P DeVincenzoRobert Lambkin-Williams
Nov 15, 2012·Human Vaccines & Immunotherapeutics·Mirte ScherpenisseFiona R M van der Klis
Mar 8, 2014·The Journal of Infectious Diseases·Kawsar R TalaatKanta Subbarao
Apr 29, 2015·The New England Journal of Medicine·Jeffrey I Cohen
May 15, 2015·Frontiers in Immunology·George William CarnellNigel James Temperton
Nov 13, 2015·Clinical and Vaccine Immunology : CVI·Wilbur H ChenKaren L Kotloff
Dec 18, 2015·Clinical and Vaccine Immunology : CVI·Patricio L AcostaFernando P Polack
May 2, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kapil BahlGiuseppe Ciaramella
Oct 29, 2017·Scientific Reports·Julián CandiaAngélique Biancotto
Jan 1, 2017·Journal of Open Research Software·Foo CheungAngélique Biancotto
Apr 20, 2019·Current Opinion in Immunology·Thomas C HeinemanMyron Levin
Dec 15, 2019·Influenza and Other Respiratory Viruses·Florian KrammerRebecca Jane Cox
Oct 15, 2020·BioRxiv : the Preprint Server for Biology·Rodney G KingScot Roberts
Oct 21, 2020·Science Translational Medicine·Barton F HaynesAnn Arvin

❮ Previous
Next ❯

Citations

May 9, 2021·International Journal of Pharmaceutics·Mattia TiboniLisbeth Illum

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
PCR
peptide
flow cytometry
lavage
biopsies
ELISA
Assay

Clinical Trials Mentioned

NCT01443936
NCT01806909

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here